[C:1]([N:4]1[C:8]2=[N:9][C:10]3[N:11]([CH3:32])[C:12](=[O:31])[N:13]([CH2:17][CH2:18][CH2:19][CH2:20][C@H:21]([O:23][Si](C(C)(C)C)(C)C)[CH3:22])[C:14](=[O:16])[C:15]=3[N:7]2[CH2:6][CH2:5]1)(=[O:3])[CH3:2].Cl.C(OCC)C.C(N(CC)CC)C>CO.O>[C:1]([N:4]1[C:8]2=[N:9][C:10]3[N:11]([CH3:32])[C:12](=[O:31])[N:13]([CH2:17][CH2:18][CH2:19][CH2:20][C@H:21]([OH:23])[CH3:22])[C:14](=[O:16])[C:15]=3[N:7]2[CH2:6][CH2:5]1)(=[O:3])[CH3:2]To a stirring solution of (R)-8-acetyl-7,8-dihydro-1-methyl-3-(5-tert-butyldimethylsilyloxyhexyl)-1H-imidazo[2,1-f]-purine-2,4(3H,6H)-dione (200 mg, 0.43 mmol) in methanol (20 ml) was added a 1.0 M solution of hydrogen chloride in diethylether (0.4 ml, 0.40 mmol). After stirring at room temperature for 30 minutes, the reaction mixture was treated with triethyamine (0.1 ml). Concentration under reduced pressure gave a white solid which was treated with water (20 ml) and stirred for 1 hour. The solid was filtered, washed with water, and dried under vacuum to provide (R)-8-acetyl-7,8-dihydro-3-(5-hydroxyhexyl)-1-methyl-1H-imidazo[2,1-f]-purine-2,4(3H,6H)-dione (CT-30260) (135 mg, 90% yield) as a white powder.
読み込み中…
